Clinical pharmacology of the serotonin receptor agonist, zolmitriptan

B. Lee Peterlin, Alan M. Rapoport

Research output: Contribution to journalArticle

Abstract

Migraine is a common, often disabling, neurovascular disease that has been shown to be associated with abnormal serotonergic activity. Drugs that modulate serotonin receptors are commonly used in the acute treatment of a migraine attack. Zolmitriptan, a 5-hydroxytryptophan1B/ 1D receptor agonist, is once such drug that is used in acute migraine therapy. Zolmitriptan is FDA approved for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks. It is rapidly absorbed and is detectable in the plasma within 2-5 min for the nasal spray formulation and within 15 min for the oral formulations. Zolmitriptan reaches peak plasma levels in 2-4 h and significant plasma levels are maintained for up to 6 h and lower levels for over 15 h. As zolmitriptan's metabolism is predominantly hepatic, patients with severe hepatic impairment should not receive zolmitriptan. However, only 25% of zolmitriptan is bound to plasma proteins and thus it is unlikely for drug interactions involving the displacement of highly protein-bound drugs. Zolmitriptan is generally very well tolerated and less than half of patients in clinical trials have reported adverse events, most of which are mild and transient, although rare serious cardiovascular events have been reported with all triptans. When patients are appropriately selected, zolmitriptan is both a safe and effective acute care migraine treatment. In this review the biological role of serotonin and its receptors is covered, followed by an indepth review of the pharmacodynamics, pharmacokinetics and efficacy of zolmitriptan. Finally, the clinical application of zolmitriptan's use in patients is dicussed.

Original languageEnglish (US)
Pages (from-to)899-911
Number of pages13
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume3
Issue number6
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

zolmitriptan
Serotonin Receptor Agonists
Clinical Pharmacology
Migraine Disorders
Serotonin Receptors
Plasmas
Drug interactions
Pharmacodynamics
Pharmaceutical Preparations
Tryptamines
Nasal Sprays
Therapeutics

Keywords

  • 5-HT receptors
  • Cardiovascular toxicity
  • Cluster headache
  • Eletriptan
  • Frovatriptan
  • Headache
  • Hepatic toxicity
  • Menstrually related migraine
  • Migraine
  • Pediatric migraine
  • Pregnancy registry
  • Rizariptan
  • Serotonin
  • Serotonin receptor
  • Serotonin receptor agonists
  • Sumatriptan
  • Triptans
  • Zolmitriptan

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. / Peterlin, B. Lee; Rapoport, Alan M.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 3, No. 6, 12.2007, p. 899-911.

Research output: Contribution to journalArticle

Peterlin, B. Lee ; Rapoport, Alan M. / Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. In: Expert Opinion on Drug Metabolism and Toxicology. 2007 ; Vol. 3, No. 6. pp. 899-911.
@article{28e6760076fe482bbcb49a9a4ac53b51,
title = "Clinical pharmacology of the serotonin receptor agonist, zolmitriptan",
abstract = "Migraine is a common, often disabling, neurovascular disease that has been shown to be associated with abnormal serotonergic activity. Drugs that modulate serotonin receptors are commonly used in the acute treatment of a migraine attack. Zolmitriptan, a 5-hydroxytryptophan1B/ 1D receptor agonist, is once such drug that is used in acute migraine therapy. Zolmitriptan is FDA approved for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks. It is rapidly absorbed and is detectable in the plasma within 2-5 min for the nasal spray formulation and within 15 min for the oral formulations. Zolmitriptan reaches peak plasma levels in 2-4 h and significant plasma levels are maintained for up to 6 h and lower levels for over 15 h. As zolmitriptan's metabolism is predominantly hepatic, patients with severe hepatic impairment should not receive zolmitriptan. However, only 25{\%} of zolmitriptan is bound to plasma proteins and thus it is unlikely for drug interactions involving the displacement of highly protein-bound drugs. Zolmitriptan is generally very well tolerated and less than half of patients in clinical trials have reported adverse events, most of which are mild and transient, although rare serious cardiovascular events have been reported with all triptans. When patients are appropriately selected, zolmitriptan is both a safe and effective acute care migraine treatment. In this review the biological role of serotonin and its receptors is covered, followed by an indepth review of the pharmacodynamics, pharmacokinetics and efficacy of zolmitriptan. Finally, the clinical application of zolmitriptan's use in patients is dicussed.",
keywords = "5-HT receptors, Cardiovascular toxicity, Cluster headache, Eletriptan, Frovatriptan, Headache, Hepatic toxicity, Menstrually related migraine, Migraine, Pediatric migraine, Pregnancy registry, Rizariptan, Serotonin, Serotonin receptor, Serotonin receptor agonists, Sumatriptan, Triptans, Zolmitriptan",
author = "Peterlin, {B. Lee} and Rapoport, {Alan M.}",
year = "2007",
month = "12",
doi = "10.1517/17425255.3.6.899",
language = "English (US)",
volume = "3",
pages = "899--911",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Clinical pharmacology of the serotonin receptor agonist, zolmitriptan

AU - Peterlin, B. Lee

AU - Rapoport, Alan M.

PY - 2007/12

Y1 - 2007/12

N2 - Migraine is a common, often disabling, neurovascular disease that has been shown to be associated with abnormal serotonergic activity. Drugs that modulate serotonin receptors are commonly used in the acute treatment of a migraine attack. Zolmitriptan, a 5-hydroxytryptophan1B/ 1D receptor agonist, is once such drug that is used in acute migraine therapy. Zolmitriptan is FDA approved for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks. It is rapidly absorbed and is detectable in the plasma within 2-5 min for the nasal spray formulation and within 15 min for the oral formulations. Zolmitriptan reaches peak plasma levels in 2-4 h and significant plasma levels are maintained for up to 6 h and lower levels for over 15 h. As zolmitriptan's metabolism is predominantly hepatic, patients with severe hepatic impairment should not receive zolmitriptan. However, only 25% of zolmitriptan is bound to plasma proteins and thus it is unlikely for drug interactions involving the displacement of highly protein-bound drugs. Zolmitriptan is generally very well tolerated and less than half of patients in clinical trials have reported adverse events, most of which are mild and transient, although rare serious cardiovascular events have been reported with all triptans. When patients are appropriately selected, zolmitriptan is both a safe and effective acute care migraine treatment. In this review the biological role of serotonin and its receptors is covered, followed by an indepth review of the pharmacodynamics, pharmacokinetics and efficacy of zolmitriptan. Finally, the clinical application of zolmitriptan's use in patients is dicussed.

AB - Migraine is a common, often disabling, neurovascular disease that has been shown to be associated with abnormal serotonergic activity. Drugs that modulate serotonin receptors are commonly used in the acute treatment of a migraine attack. Zolmitriptan, a 5-hydroxytryptophan1B/ 1D receptor agonist, is once such drug that is used in acute migraine therapy. Zolmitriptan is FDA approved for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks. It is rapidly absorbed and is detectable in the plasma within 2-5 min for the nasal spray formulation and within 15 min for the oral formulations. Zolmitriptan reaches peak plasma levels in 2-4 h and significant plasma levels are maintained for up to 6 h and lower levels for over 15 h. As zolmitriptan's metabolism is predominantly hepatic, patients with severe hepatic impairment should not receive zolmitriptan. However, only 25% of zolmitriptan is bound to plasma proteins and thus it is unlikely for drug interactions involving the displacement of highly protein-bound drugs. Zolmitriptan is generally very well tolerated and less than half of patients in clinical trials have reported adverse events, most of which are mild and transient, although rare serious cardiovascular events have been reported with all triptans. When patients are appropriately selected, zolmitriptan is both a safe and effective acute care migraine treatment. In this review the biological role of serotonin and its receptors is covered, followed by an indepth review of the pharmacodynamics, pharmacokinetics and efficacy of zolmitriptan. Finally, the clinical application of zolmitriptan's use in patients is dicussed.

KW - 5-HT receptors

KW - Cardiovascular toxicity

KW - Cluster headache

KW - Eletriptan

KW - Frovatriptan

KW - Headache

KW - Hepatic toxicity

KW - Menstrually related migraine

KW - Migraine

KW - Pediatric migraine

KW - Pregnancy registry

KW - Rizariptan

KW - Serotonin

KW - Serotonin receptor

KW - Serotonin receptor agonists

KW - Sumatriptan

KW - Triptans

KW - Zolmitriptan

UR - http://www.scopus.com/inward/record.url?scp=37348999890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37348999890&partnerID=8YFLogxK

U2 - 10.1517/17425255.3.6.899

DO - 10.1517/17425255.3.6.899

M3 - Article

C2 - 18028032

AN - SCOPUS:37348999890

VL - 3

SP - 899

EP - 911

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 6

ER -